healthcare

Plasma is still a winner for the healthcare giant, but vaccinations face hurdles.

This commercial med-tech is valued at just ~A$40m despite having innovative tech, market adoption and a partnership with a global giant.

Could this Australian-American healthcare stalwart hit $60/share?

Real Asset Management's Matthew Strotton is bullish on this often overlooked area of healthcare real estate investing.

In this wire, we explain why one of our flagship funds shifted to a full-time healthcare focus.

Despite pressure on consumer spending, consumers prioritise trusted brands for their health-related needs and Haleon is a beneficiary.

Wilson Asset Management’s Dania Zinurova explains the big themes she chases for WAM Alternative Assets through her investments.

The Pharma & Biotech market had a relatively positive month with 41.5% of the coverage universe posting positive share price movements for the month of September. Over...

Why the healthcare sector could gain momentum even as economic growth potentially slows and the U.S. readies for a presidential election.

With volatility persisting investors may want to consider this defensive sector, supported by valuations and long-term growth drivers.